Monoclonal antibodies (mAbs) have been used in the treatment of various diseases for over
20 years and combine high specificity with generally low toxicity. Their pharmacokinetic …

Cyclophosphamide is an extensively used anticancer and immunosuppressive agent. It is a
prodrug undergoing a complicated process of metabolic activation and inactivation. …

There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM)
in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between …

Pharmacokinetic–pharmacodynamic modeling using non-linear mixed effects modeling (NONMEM)
is a powerful yet challenging technique, as the software is generally accessed from …

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable
and clear relationships exist between exposure and treatment outcomes, fixed dosing is still …

Purpose This review provides an overview of the current challenges in oral targeted antineoplastic
drug (OAD) dosing and outlines the unexploited value of therapeutic drug monitoring (…

This article reviews the pharmacokinetics of heroin after intravenous, oral, intranasal,
intramuscular and rectal application and after inhalation in humans, with a special focus on heroin …

The large-scale genetic profiling of tumours can identify potentially actionable molecular
variants for which approved anticancer drugs are available 1 , 2 – 3 . However, when patients …

The pharmacokinetics of miltefosine in leishmaniasis patients are, to a great extent, unknown.
We examined and characterized the pharmacokinetics of miltefosine in a group of patients …

Handling of data below the lower limit of quantification ( LLOQ ), below the limit of quantification
( BLOQ ) in population pharmacokinetic ( PopPK ) analyses is important for reducing …